Stock 603233 DASHENLIN PHARMACEUTICAL GROUP CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus DaShenLin Pharmaceutical Group Co., Ltd.

Equities

603233

CNE100002RG2

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-07-11 pm EDT 		5-day change 1st Jan Change
13.12 CNY -2.60% Intraday chart for DaShenLin Pharmaceutical Group Co., Ltd. -7.48% -47.31%
May. 07 DaShenLin Pharmaceutical Group Co., Ltd. commences an Equity Buyback Plan for CNY 200 million worth of its shares, under the authorization approved on April 1, 2024. CI
Apr. 28 DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Evolution of the average Target Price on DaShenLin Pharmaceutical Group Co., Ltd.

Price target over the last 5 years

History of analyst recommendation changes

920a4e10.h1mMgCnFZwa1TwQoC7QSrYGO98BDIYlV2iClECmC9jQ.5Wm80BvoI1mMPkNrTNVV9fH7p60sUv8lrRbxamDghX_NYdnueqk2cvkBUQ~e7f6a9a80a236af90be668f028efa373

Analyst Recommendations on DaShenLin Pharmaceutical Group Co., Ltd.

UBS Adjusts Dashenlin Pharmaceutical's Price Target to 40 Yuan From 73.5 Yuan, Keeps at Buy MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
13.12 CNY
Average target price
30.54 CNY
Spread / Average Target
+132.81%
High Price Target
34 CNY
Spread / Highest target
+159.15%
Low Price Target
22.5 CNY
Spread / Lowest Target
+71.49%

Consensus detail

Consensus revision (last 18 months)

Analysts covering DaShenLin Pharmaceutical Group Co., Ltd.

UBS

Ratings for DaShenLin Pharmaceutical Group Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. 603233 Stock
  4. Consensus DaShenLin Pharmaceutical Group Co., Ltd.